#Vienna #Austria #PF Products #AVVie GmbH #AngelValve

PF Products & Features GmbH Expands Portfolio through Acquisition of AVVie GmbH

On August 5, 2026, PF Products & Features GmbH, based in Vienna, announced its acquisition of AVVie GmbH, a company dedicated to developing groundbreaking technologies in heart valve solutions. Founded by renowned cardiac surgeon Professor Werner Mohl, AVVie has introduced the AngelValve™ Augmentation System—a novel transcatheter solution aimed at addressing the significant medical need for treating mitral regurgitation, a condition affecting millions worldwide.

Understanding Mitral Regurgitation

Mitral regurgitation occurs when blood leaks backward into the left atrium of the heart. It affects over 13 million individuals across Europe and the United States. Alarmingly, only a small fraction—less than 5% of patients suffering from moderate to severe mitral regurgitation—currently receive appropriate treatment. This gap in care presents a critical challenge that PF aims to tackle, with a vision to enhance the quality of life for millions affected by this condition.

The AngelValve™ Augmentation System

The AngelValve system is a significant advancement in minimally invasive treatments for mitral valve diseases, particularly for patients with limited options. Its innovative design allows for effective treatment in patients who might otherwise have been left without viable therapeutic avenues. By bridging this treatment gap, PF hopes to provide a true lifeline for those dealing with this serious health issue.

Strategic Synergy and Growth Prospects

By integrating AVVie’s intellectual property and R&D capabilities with PF’s established infrastructure for product development, clinical trials, and commercialisation, the newly formed entity is well-positioned to accelerate innovation in heart valve treatments.

Katharina Kiss, MD, the CEO of PF, remarked, “The acquisition reflects our ongoing commitment to developing breakthrough structural procedures for heart diseases. Merging AVVie’s technical excellence with our expertise ensures we are equipped to advance the AngelValve™ platform and deliver meaningful innovations to clinicians and patients globally.”

In parallel, Siegfried Einhellig, PF’s COO, expressed excitement about leveraging both companies' strengths, stating, “This combination taps into exceptional technical talent and proven development capabilities. We are thrilled to transform this innovation into effective treatments.”

Looking Ahead

The terms of the acquisition remain undisclosed, but the collaboration promises to significantly enhance PF’s capabilities in the cardiovascular technology sector. As they pave the way for innovative approaches to heart valve conditions, both companies are united in their mission to elevate patient care standards and address unmet medical needs.

With over 25 years of expertise in developing innovative cardiovascular solutions, PF is committed to its global outreach within roughly 70 countries, supported by its manufacturing facilities in Europe, Asia, and Brazil. For further details on their initiatives and products, visit productsandfeatures.com.